Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2015-09-29 Director's Dealing
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares
Director's Dealing Classification · 98% confidence The document explicitly details the CEO, Geoffrey McDonough, purchasing shares as part of a Long-Term Incentive (LTI) programme and subsequently divesting a portion of his existing shares to cover tax liabilities related to a previous LTI programme. This activity—the transaction in own shares by an executive—is a form of insider dealing or director's dealing. This aligns directly with the definition for 'Director's Dealing' (Code: DIRS). Although it involves share transactions, it is specifically about executive personal holdings/transactions, not a general share repurchase program (POS) or a capital change announcement (SHA). The document is short and contains the full information, so it is not an RPA.
2015-09-29 English
Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a positive opinion received from the CHMP (Committee for Medicinal Products for Human Use) regarding a marketing authorization for a drug (Elocta™). This type of announcement, detailing regulatory milestones, clinical trial results summaries, and collaboration updates, is characteristic of an initial public disclosure of significant corporate news, often preceding a formal earnings report or a detailed regulatory filing. It is not a full Annual Report (10-K), an Interim Report (IR), a transcript (CT), or a formal proxy/governance document. Since it is a press release announcing a major regulatory/product development event, it fits best under the general category for significant regulatory announcements that aren't specifically covered by other codes, making 'Regulatory Filings' (RNS) the most appropriate fallback, although 'Earnings Release' (ER) is sometimes used for major news, this is specifically regulatory/product focused. Given the options, RNS serves as the best general regulatory announcement category for non-standard filings like this press release.
2015-09-25 English
Biogen och Sobi erhåller CHMP rekommendation för Elocta(TM) (rFVIIIFc) för behandling av hemofili A
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a specific corporate event: the Committee for Medicinal Products for Human Use (CHMP) recommendation for marketing authorization for the drug Elocta™ (rFVIIIFc) for Hemophilia A treatment. This is a time-sensitive announcement of a significant regulatory/development milestone, not a comprehensive annual report (10-K), a quarterly report (IR), or a full transcript (CT). It is a direct announcement of a key event, which aligns best with an Earnings Release (ER) if it were financial results, but since it is a regulatory/development update, it fits best under the general category of a significant corporate announcement. Given the options, this type of announcement, which is often released alongside or instead of a formal earnings release to highlight major news, is frequently classified as an Earnings Release (ER) in databases when it pertains to operational/product milestones, or sometimes as a Regulatory Filing (RNS) if it's purely regulatory news. However, since it details clinical trial results (A-LONG, Kids A-LONG) and partnership updates, it functions as a major operational update. In many financial databases, major product/regulatory milestones announced via press release are categorized under ER if they drive market perception, or RNS if they are purely regulatory filings. Given the structure and content (major milestone announcement), ER is a strong candidate, but RNS is the safest fallback for non-standard regulatory/corporate news. Since it is a specific, non-financial operational/regulatory update, and not a standard earnings report, I will classify it as a Regulatory Filing (RNS) as it is a formal announcement of a regulatory step (CHMP recommendation) that doesn't fit the other specific categories like DIV, CAP, or MANG.
2015-09-25 Swedish
Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
Transaction in Own Shares Classification · 98% confidence The document explicitly details the board of directors exercising an authorization to repurchase shares ('repurchase of class C shares') which was previously resolved by the annual general meeting. This action directly relates to the company buying back or selling its own shares to fulfill commitments under an incentive program. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). It is not a general financing update (CAP) or a general share issue (SHA), but a specific repurchase action.
2015-09-11 English
Swedish Orphan Biovitrum AB (publ) : Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated September 11, 2015, detailing the Board's decision to utilize a repurchase authorization to acquire C-shares. The core subject is the company buying back its own shares (C-aktier) to secure commitments under an incentive program. This action directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase). Therefore, the appropriate filing code is POS.
2015-09-11 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report ('Q2 RAPPORT 2015') for Sobi. It contains detailed financial statements, operational overviews, key performance indicators, and management commentary for the second quarter of 2015. It is not an announcement of a report (RPA) nor a simple regulatory filing (RNS), as it provides substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2015
2015-07-16 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.